缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究

Clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure

目的观察缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效及安全性。方法 86例慢性心力衰竭患者随机分为试验组42例和对照组44例。试验组口服缬沙坦80 mg·d^(-1),阿托伐他汀10 mg·d^(-1);对照组口服贝那普利10 mg·d^(-1),阿托伐他汀10 mg·d^(-1)。2组患者均连续应用3个月。观察2组治疗后的总有效率、血清脑钠肽(BNP)水平及不良反应发生情况。结果治疗后,试验组和对照组临床总有效率分别为90.48%和86.36%,差异无统计学意义(P>0.05)。治疗后,2组患者血清BNP水平均显著降低(P<0.05),试验组显著低于对照组(P<0.05)。试验组患者用药期间不良反应发生率为11.90%,对照组为6.82%,差异无统计学意义(P>0.05)。结论缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床有效率和不良反应无明显差别。

Objective To evaluated the clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients. Methods Eighty- six cases with chronic cardiac failure were recruited in this study and randomly divided into treatment group（ n = 42） and control group（ n = 44）.Patients in treatment group were received valsartan 80 mg · d^（-1）orally plus atorvastatin 10 mg · d^（-1）orally,patients in control group received benazepril 10 mg·d^（-1）orally plus atorvastatin 10 mg · d^（-1）orally. The course was 3 months. After treatment,the clinical efficacy,serum level of brain natriuretic peptide and adverse event were compared between the two groups. Results The total clinical efficacy of treatment group and control group were 90. 48% and 86. 36% respectively with no statistical difference（ P〈0. 05）. The serum level of brain natriuretic peptide significant decreased in the both groups（ P〈0. 05） after treatment. And the serum level of brain natriuretic peptide in treatment group was significant lower compared with that in control group after treatment（ P〈0. 05）.There were no statistical difference on adverse drug reactions between two groups（ P〉0. 05）. Conclusion The clinical efficacy and safety were not significantly different for valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients.